The stock of Clover Health Investments Corp (NASDAQ:CLOV) last traded at $2.97, up 4.95% from the previous session.
CLOV stock price is now -10.98% away from the 50-day moving average and -16.65% away from the 200-day moving average. The market capitalization of the company currently stands at $1.51B.
With the price target of $6, Craig Hallum recently initiated with Buy rating for Clover Health Investments Corp (NASDAQ: CLOV). On October 07, 2024, UBS recently initiated its ‘Neutral’ rating on the stock quoting a target price of $4, while ‘Cowen’ rates the stock as ‘Market Perform’
In other news, Reynoso Jamie L., CEO, Medicare Advantage sold 20,450 shares of the company’s stock on Jun 17 ’25. The stock was sold for $58,487 at an average price of $2.86. Upon completion of the transaction, the CEO, Medicare Advantage now directly owns 3,196,401 shares in the company, valued at $9.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 17 ’25, Officer JAMIE REYNOSO bought 20,450 shares of the business’s stock. A total of $59,714 was incurred on buying the stock at an average price of $2.92. A total of 24.92% of the company’s stock is owned by insiders.
During the past 12 months, Clover Health Investments Corp has had a low of $1.01 and a high of $4.87. The fifty day moving average price for CLOV is $3.3364 and a two-hundred day moving average price translates $3.563425 for the stock.
The latest earnings results from Clover Health Investments Corp (NASDAQ: CLOV) was released for 2025-03-31. The net profit margin was -1.69% and return on equity was -7.75% for CLOV. The company reported revenue of $462.33 million for the quarter, compared to $346.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 33.27 percent.
